Trial Now Recruiting: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. (NCT06563999)
WHY IT MATTERS
If you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.
NCT ID: NCT06563999 Status: RECRUITING Conditions: Lung Cancer Stage III, Mutation Phase: PHASE2 Enrollment: 120 Sponsor: Sun Yat-sen University Summary: This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.
YOU CAN ACT ON THIS
If you have stage III NSCLC with a rare mutation and haven't started treatment yet, contact Sun Yat-sen University or search NCT06563999 on clinicaltrials.gov to learn if you qualify and how to enroll.